Aclaris Therapeutics appoints Douglas Manion as President and COO effective August 1, 2022

Aclaris Therapeutics, Inc.

Douglas Manion appointed President and COO effective August 1, 2022; Neal Walker remains CEO.
Receives annual base salary of $490,000, target annual bonus of 40% of salary.
Granted stock options for 217,800 shares at $13.62 exercise price and RSU award for 62,300 shares.
Equity awards vest over four years; severance includes 12 months base salary plus COBRA if terminated without cause.
Previously EVP R&D at Arena Pharmaceuticals and held leadership roles at BMS.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Douglas Manion

President and Chief Operating Officer

ACRS · Aclaris Therapeutics, Inc.

Effective: 2022-08-01
Filed: August 1, 2022, 7:59 PM ET

appointed Douglas Manion, M.D., FRCP (C), as the Company’s President and Chief Operating Officer effective August 1, 2022.

Role change

Neal Walker

President

ACRS · Aclaris Therapeutics, Inc.

Effective: 2022-08-01
Successor: Douglas Manion
Filed: August 1, 2022, 7:59 PM ET

Neal Walker will no longer serve as the Company’s President, but will continue to serve as the Company’s Chief Executive Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Douglas Manion was appointed as President and Chief Operating Officer at Aclaris Therapeutics, Inc..

Action: appointed
Role: President and Chief Operating Officer

Exact text from the filing

appointed Douglas Manion, M.D., FRCP (C), as the Company’s President and Chief Operating Officer effective August 1, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Neal Walker changed role as President at Aclaris Therapeutics, Inc..

Action: no longer serve as
Role: President

Exact text from the filing

Neal Walker will no longer serve as the Company’s President, but will continue to serve as the Company’s Chief Executive Officer.

View on SEC.gov

Aclaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-22-011475

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.